Vivek Ramaswamy is the Founder and Chief Executive Officer of Roivant Sciences. Roivant’s mission is to systemically reduce the time and cost of drug development and to advance important medicines for patients in disease areas where the magnitude of R&D investment from industry is disproportionately low relative to societal needs.

Roivant has unique approach to industrial organization: the company builds “Vants” – nimble, entrepreneurial biotech companies with a unique approach to sourcing talent, aligning economic incentives, and deploying technology to drive greater efficiency in R&D. Roivant also incubates new businesses focused on improving drug development and commercialization through applications of healthcare data.

Roivant has over 700 employees and over 30 investigational medicines in development across its family of companies and has raised over $3 billion in capital to support its mission. Companies in the Roivant family today include Myovant, Axovant, Arbutus, Urovant, Enzyvant, Dermavant, Genevant, Metavant, Altavant, Immunovant, Sinovant, and Datavant. Roivant recently announced the initiation of a Biologics License Application (BLA) submission for an investigational regenerative therapy designed to reconstitute the immune systems of children born with a rare and fatal pediatric disease.

Prior to founding Roivant in 2014, Mr. Ramaswamy was an investor in the biotechnology sector. He received his A.B. summa cum laude in biology from Harvard College and his J.D. from Yale Law School, where he was a Paul & Daisy Soros Fellow.